Hyundai ADM Bio

It was an honor to present our latest research on Penetrium™ at the AACR-NCI-EORTC 2025 International Conference. We would like to express our sincere appreciation to all who visited our presentation and showed great interest and engagement. Co-developed by Hyundai ADM bio and Hyundai Bioscience, this study introduced the potential of a CAF-targeting therapeutic strategy applicable beyond cancer, extending to autoimmune and neurodegenerative diseases.   Moving forward, Penetrium™ will continue to be developed as a platform therapy that regulates disease-associated fibroblasts (DAFs) — addressing the fibrotic and inflammatory roots underlying systemic diseases. Our goal is to go beyond the boundaries of conventional cancer treatment and reshape the paradigm of the oncobiosphere by expanding this approach to a broader range of chronic diseases.   #AACR_NCI_EORTC2025 #Penetrium #CancerResearch #HyundaiBioscience #HyundaiADMbio #TranslationalResearch

We just wrapped up AACR–NCI–EORTC (US · Oct 26). Here’s our recap. This year, Hyundai ADM Bio, together with our parent company Hyundai Bioscience, presented Penetrium™ as a microenvironment-restoring platform that targets CAF/DAF biology to normalize the ECM—so therapies can actually reach their targets and perform as intended.   - Oncology highlights. Across models, Penetrium™ combinations improved delivery, reduced primary burden, and blocked metastasis in multiple settings: with chemotherapy (e.g., paclitaxel in TNBC), anti-VEGF therapy (bevacizumab in lung cancer), and immune checkpoint therapy (anti-PD-1 in orthotopic TNBC). In TNBC, simultaneous anti-PD-1 combination achieved up to 96% reduction in bioluminescent tumor signal, and tissue readouts were consistent with ECM remodeling (MMP-9↓, E-cadherin↑; in lung cancer, MMP-9↓/VEGF↓). We also showed organoid–CAF systems where Penetrium™ restored gemcitabine sensitivity, and naturally occurring canine mammary cancer cases supporting translational relevance.   - Autoimmune disease expansion. In rheumatoid arthritis, combining Penetrium™ with methotrexate produced complete remission cases and improved histology. In multiple sclerosis models, Penetrium™ monotherapy and combinations with ozanimod lowered clinical scores versus vehicle, with combinations surpassing ozanimod alone in several arms. Signals were also observed in psoriasis (skin thickness & PASI-like components) and Crohn’s disease (disease activity & histology), consistent with an ECM-centric, delivery-first approach rather than adding immunosuppression.   Many thanks to those many scientists, clinicians, and industry colleagues who engaged with us during the meeting. We’ll share follow-up figures and mechanism visuals in the coming days to continue the discussion around ECM restoration and pseudo-resistance—and how these insights can translate into better outcomes across disease areas.   #Penetrium #CAF #DAF #ECMRestoration #TumorMicroenvironment #Oncology #Autoimmune #DrugDelivery #HyundaiADMBio #HyundaiBioscience #AACR_NCI_EORTC

Penetrium™ Expands the Boundaries of Autoimmune Therapy Hyundai ADM Bio and Hyundai Bioscience presented new preclinical findings on Penetrium™ at the AACR–NCI–EORTC 2025 Conference in Boston, USA. The study confirmed that Penetrium™ demonstrated consistent efficacy across four key autoimmune diseases — rheumatoid arthritis, multiple sclerosis, psoriasis, and Crohn’s disease — using the same compound, dosage, and administration method. Unlike conventional immunosuppressants, Penetrium™ restores the extracellular matrix (ECM) and tissue microenvironment (TME), helping the immune system regain its natural balance. This research is medically significant, as it demonstrates that the ECM/TME restoration mechanism first observed in cancer also applies to autoimmune diseases, revealing a shared pathological axis between the two. Moving forward, Hyundai ADM Bio and Hyundai Bioscience plan to advance Penetrium™ into clinical development, seeking FDA Fast Track and Breakthrough Therapy designations while establishing global partnerships to accelerate its transition into a Microenvironment Restoration Therapy (MERT) platform for autoimmune and related diseases. #HyundaiBioscience #HyundaiADMBio #Penetrium #AACR_NCI_EORTC2025 #Innovation #AutoimmuneDisease #CancerResearch #MERT #DrugDevelopment #ClinicalResearch

Hyundai ADM Bio and Hyundai Bioscience Unveiled Breakthrough Findings on the Common Pathophysiology Connecting Cancer, Autoimmune On October 14, 2025, Hyundai ADM Bio, together with Hyundai Bioscience, announced the preclinical mid-term results for Penetrium™, our innovative therapeutic platform designed to restore the extracellular matrix (ECM) and overcome pseudo-resistance. This fundamental barrier prevents effective drug delivery. The presentation was held at the Korea Press Center in Seoul. 🗝️ Key Highlights from the Announcement: Pseudo-resistance refers to drug unresponsiveness caused not by genetic mutations, but by the pathological stiffening of the ECM, which physically blocks drugs and immune cells from reaching disease sites. Penetrium™ normalizes this abnormal ECM, reopening the biological “communication channels” between cells and re-enabling the immune system to function properly—without immune suppression. The preclinical results demonstrated robust efficacy in rheumatoid arthritis and multiple sclerosis models, including outcomes of complete remission and functional recovery. These groundbreaking findings were subsequently presented at the AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston (October 22–25, 2025), where Penetrium™’s mechanism for overcoming pseudo-resistance was unveiled to a global scientific audience. 🎤 Key Perspectives on the Breakthrough: “Penetrium™ represents a paradigm shift from immune suppression to immune normalization—a novel therapeutic concept that restores the fundamental disease environment.” — Prof. Jin-Ho Choi, Dankook University “This was the first step toward validating Penetrium™ as a platform drug addressing shared pathological mechanisms across multiple refractory diseases.” — Won-Dong Cho, Co-CEO, Hyundai ADM Bio 📰 For a more detailed look at our findings, please see the press coverage below: 현대바이오 “류마티스·다발성경화증에서도 ‘페니트리움 효능’ 확인” https://lnkd.in/grF3FrVA #HyundaiADMBio #HyundaiBioscience #Penetrium #Pseudo_Resistance #PseudoResistance #ECMRestoration #AACR_NCI_EORTC #Oncology #AutoimmuneDisease #InnovationInMedicine #MolecularTargets #DrugDelivery

📢 Paradigm Shift Imminent! Hyundai ADM Bio and its parent company, Hyundai Bioscience, will unveil the “ECM Restoration Paradigm” in Boston, marking a major leap forward in the clinical expansion of their innovative therapeutic platform, Penetrium™ — now approaching significant milestones in autoimmunity. 🗝️ Key Achievements & Highlights Safety and Oncology Trials: Penetrium™ has received Phase 1 Clinical Trial Approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for its prostate cancer indication, expanding its potential in oncology. Accelerating Autoimmunity: We are actively advancing clinical expansion into autoimmune indications including Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, and Crohn’s Disease, underscoring our commitment to providing a fundamentally improved therapeutic approach for serious immune-mediated conditions. 🤝 Join Us in Boston! We will unveil core preclinical results for autoimmune diseases at a leading global anticancer research conference in Boston. Conference: AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics Dates: October 23 (Thu) – 25 (Sat), 2025 💡 Vision Penetrium™ represents the starting point for transforming the current immunosuppression-centric paradigm into one based on pseudo-resistance normalization. Our vision is to evolve this into an integrated therapeutic platform that addresses cancer, autoimmune through a unified pathological mechanism. We look forward to sharing more about this transformative journey in Boston. #Biotech #ECM_Restoration #Penetrium #AutoimmuneDiseases #AACR_NCI_EORTC #HyundaiADMbio

In a mouse model of rheumatoid arthritis, the combination of Penetrium™ and methotrexate (MTX) demonstrated greater therapeutic efficacy than MTX alone — with cases of complete remission observed. Unlike conventional immunosuppressants, Penetrium™ enhances drug delivery by improving ECM permeability, allowing drugs to reach target cells more effectively. These findings suggest that Penetrium™ can amplify treatment outcomes without additional immune suppression, offering a new direction in autoimmune disease therapy. #HyundaiBioscience #Penetrium™ #RheumatoidArthritis #DrugDevelopment #Innovation #AutoimmuneDisease #ClinicalResearch

🧩 When the ECM stiffens, communication breaks — and drugs can’t get through. In rheumatoid arthritis, pathological remodeling of the extracellular matrix (ECM) alters immune cell trafficking and disrupts intercellular communication. This dysfunctional microenvironment doesn’t just fuel chronic inflammation — it can also create a form of pseudo-resistance, where therapies fail not because of the drug itself, but because the drug cannot penetrate the ECM barrier. This perspective, first explored in cancer research, is now being recognized in autoimmune diseases as well — shifting how we think about treatment failure and resistance. 📚 Reference: Nat Rev Rheumatol. 2023 Oct;19(10):627–639. #RheumatoidArthritis #ECM #PseudoResistance #Immunology #AutoimmuneDiseases #DrugDelivery #BiomedicalResearch

At Hyundai Bioscience, we explore the mechanisms behind why certain drugs fail to reach their intended cellular targets — not due to genetic resistance, but due to physical barriers in the extracellular matrix (ECM). Pseudo-resistance refers to a state where drugs cannot reach target cells because of abnormal ECM structures, not because of mutations in the cells themselves. This concept was first identified in cancer treatment and has since been observed in autoimmune diseases as well. By understanding and overcoming pseudo-resistance, we aim to develop therapies that truly reach where they are needed most. #HyundaiBioscience #Pseudo_Resistance #ECM #DrugDelivery #BiomedicalResearch

📌 Pseudo-Resistance “When anticancer drugs fail to reach tumor cells, it may result in pseudo-resistance—a barrier unrelated to genetic mutations.” 👉 Check the image for an explanation. #PseudoResistance #DrugPenetration #SolidTumors #HyundaiBioscience #CancerTherapeutics #OncologyInnovation

📌 PD-1 (Programmed Cell Death Protein 1) "PD-1 is a checkpoint protein that tumors exploit to escape immune attacks. Blocking PD-1 has transformed the landscape of cancer immunotherapy." 👉 Curious how immune evasion works? Check the image. #PD1 #Immunotherapy #CancerImmunity #HyundaiBioscience #CancerTherapeutics #OncologyInnovation